<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01378104</url>
  </required_header>
  <id_info>
    <org_study_id>PEGASYS100:80</org_study_id>
    <nct_id>NCT01378104</nct_id>
  </id_info>
  <brief_title>100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)</brief_title>
  <official_title>The Response of Reducing Dose of Peginterferon Alfa-2a in Koreans With Chronic Hepatitis C Genotype 1; Randomized Controlled Multicenter Study 100% Versus 80%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHIC Ilsan hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Randomized controlled multicenter study

        2. The response of reducing dose of peginterferon alfa-2a in Koreans with chronic hepatitis
           C genotype 1

        3. IL28B polymorphism in Koreans with CHC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The virologic response of Koreans to combination therapy for chronic hepatitis C is similar
      to non-Asians; however, dose modification occurs more frequently in Koreans.

      -When we evaluated the rates of peginterferon α-2a and ribavirin dose modifications and their
      effect on the virologic response in Koreans, we suggested that using at least 80% of the
      peginterferon α-2a dose in Koreans not only maintains SVR but also reduces drug side effects
      during the entire treatment period and a lower dose of ribavirin may be as efficacious as a
      standard dose(Korean J Intern Med 2009;24:203-211).

      So we investigate whether the group of 80% use dosage of peginterferon alfa-2a did not show
      inferior response rather than that of 100 % use dosage group and minimize the adverse events.

      There are recently reports that Koreans have favorable IL28B SNP for CHC treatment.

      -We investigate the IL28B polymorphism in Koreans with CHC and this result can effect on the
      SVR depending on the dosage of peginterferon alfa 2a
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virologic Response Depending on the Dosage of Peginterferon Alfa 2a</measure>
    <time_frame>post treatment 24 weeks</time_frame>
    <description>We investigate whether the SVR between 100% and 80% group of peginterferon alfa 2a is not different.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL28B Polymorphism Effect on SVR</measure>
    <time_frame>post treatment 24 weeks</time_frame>
    <description>We additionally investigate the IL28B polymorphism and this result can effect on the SVR depending on dosage of peginterferon alfa-2a.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Sustained Virologic Response</condition>
  <condition>IL28B Polymorphism</condition>
  <arm_group>
    <arm_group_label>80% dosage group of peginterferon alfa 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100% dosage group of peginterferon alfa 2a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These group patients would be treated with standard dose 180 ug/week for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa 2a (pegasys)</intervention_name>
    <description>dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable</description>
    <arm_group_label>80% dosage group of peginterferon alfa 2a</arm_group_label>
    <other_name>Roche</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a (pegasys)</intervention_name>
    <description>These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.</description>
    <arm_group_label>100% dosage group of peginterferon alfa 2a</arm_group_label>
    <other_name>Roche</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic hepatitis C (anti HCV+, HCV RNA +)

          -  Genotype 1

          -  over 18 year-old

          -  Pregnancy test negative if women of childbearing age

        Exclusion Criteria:

          -  pregnant women or breast feeding women

          -  systemic chemotherapy or steroid therapy before 6 months of trial

          -  Coinfection with HAV, HBV, and HIV

          -  Other liver disease such as hemochromatosis, autoimmune hepatitis, metabolic liver
             disease, alcoholic liver disease, toxic hepatitis

          -  Hepatocellular carcinoma

          -  Evidence of decompensation such as variceal bleeding,ascites, encephalopathy

          -  ANC less than 1500, platelet less than 90k

          -  Cr more than 1.5 of UNL

          -  Severe psychiatric problem

          -  Poorly controlled thyroid disease

          -  Severe retinopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung Hyun Kwon, MD, Assistant professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunghyang University Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Chunchun Medical center</name>
      <address>
        <city>Chunchun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghungnam National University hospital</name>
      <address>
        <city>Daejun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konyang University hospital</name>
      <address>
        <city>Daejun</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Incheon St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University, Ilsan Paik Hospital</name>
      <address>
        <city>Koyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHIC Ilsan hospital</name>
      <address>
        <city>Koyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University, Pusan Paik Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan university</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University, Wonju Hospital</name>
      <address>
        <city>Wonju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2011</study_first_posted>
  <results_first_submitted>December 14, 2012</results_first_submitted>
  <results_first_submitted_qc>February 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 8, 2013</results_first_posted>
  <last_update_submitted>February 3, 2013</last_update_submitted>
  <last_update_submitted_qc>February 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Jung Hyun Kwon</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>reducing dose of peginterferon</keyword>
  <keyword>chronic hepatitis c</keyword>
  <keyword>Koreans</keyword>
  <keyword>IL28B polymorphism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>enrollment date : 2009-2011 recruitment period : 2009-2012 type location: 14 university hospital</recruitment_details>
      <pre_assignment_details>no excluded patients before assignment to groups</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>100% Dosage Group of Peginterferon Alfa 2a</title>
          <description>These group patients would be treated with standard dose 180 ug/week for 48 weeks.
peginterferon alfa-2a (pegasys) : These patients would be treated with standard dose 180ug /week for 48 weeks.
In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.</description>
        </group>
        <group group_id="P2">
          <title>80% Dosage Group of Peginterferon Alfa 2a</title>
          <description>This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
peginterferon alfa 2a (pegasys) : dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>100% Dosage Group of Peginterferon Alfa 2a</title>
          <description>These group patients would be treated with standard dose 180 ug/week for 48 weeks.
peginterferon alfa-2a (pegasys) : These patients would be treated with standard dose 180ug /week for 48 weeks.
In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.</description>
        </group>
        <group group_id="B2">
          <title>80% Dosage Group of Peginterferon Alfa 2a</title>
          <description>This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
peginterferon alfa 2a (pegasys) : dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="92"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="178"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" spread="10.6"/>
                    <measurement group_id="B2" value="48.7" spread="11.5"/>
                    <measurement group_id="B3" value="48.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Virologic Response Depending on the Dosage of Peginterferon Alfa 2a</title>
        <description>We investigate whether the SVR between 100% and 80% group of peginterferon alfa 2a is not different.</description>
        <time_frame>post treatment 24 weeks</time_frame>
        <population>We present the result of intention-to-treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>100% Dosage Group of Peginterferon Alfa 2a</title>
            <description>These group patients would be treated with standard dose 180 ug/week for 48 weeks.
peginterferon alfa-2a (pegasys) : These patients would be treated with standard dose 180ug /week for 48 weeks.
In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.</description>
          </group>
          <group group_id="O2">
            <title>80% Dosage Group of Peginterferon Alfa 2a</title>
            <description>This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
peginterferon alfa 2a (pegasys) : dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virologic Response Depending on the Dosage of Peginterferon Alfa 2a</title>
          <description>We investigate whether the SVR between 100% and 80% group of peginterferon alfa 2a is not different.</description>
          <population>We present the result of intention-to-treat analysis.</population>
          <units>participants who achieved SVR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL28B Polymorphism Effect on SVR</title>
        <description>We additionally investigate the IL28B polymorphism and this result can effect on the SVR depending on dosage of peginterferon alfa-2a.</description>
        <time_frame>post treatment 24 weeks</time_frame>
        <population>The patients who agreed to check the genotype were analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Favourable IL28B Genotype</title>
            <description>These group patients show the IL28B rs12979860CC and rs8099917TT.</description>
          </group>
          <group group_id="O2">
            <title>The Patients With Unfavourable IL28B Genotype</title>
            <description>These group patients show the IL28B rs12979860 CT or TT and rs8099917 TG or GG.</description>
          </group>
        </group_list>
        <measure>
          <title>IL28B Polymorphism Effect on SVR</title>
          <description>We additionally investigate the IL28B polymorphism and this result can effect on the SVR depending on dosage of peginterferon alfa-2a.</description>
          <population>The patients who agreed to check the genotype were analysed.</population>
          <units>percentage of SVR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>100% Dosage Group of Peginterferon Alfa 2a</title>
          <description>These group patients would be treated with standard dose 180 ug/week for 48 weeks.
peginterferon alfa-2a (pegasys) : These patients would be treated with standard dose 180ug /week for 48 weeks.
In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.</description>
        </group>
        <group group_id="E2">
          <title>80% Dosage Group of Peginterferon Alfa 2a</title>
          <description>This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
peginterferon alfa 2a (pegasys) : dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CBC</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>laboratory adverse events</sub_title>
                <description>Neutropenia, thrombocytopenia, anemia</description>
                <counts group_id="E1" events="54" subjects_affected="45" subjects_at_risk="92"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kwon</name_or_title>
      <organization>the Catholic University of Korea</organization>
      <phone>+82322805886</phone>
      <email>doctorkwon@catholic.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

